Frequent Emergency Medicine Decision-Making Factors in ABSSSI Treatment
Clinical factors such as severity of infection on presentation and underlying comorbidities were the main factors influencing treatment decisions.
In-Depth Focus from IDWeek 2017: Skin Infections
Dalbavancin Safe and Effective for ABSSSI in Patients With SIRS
Dalbavancin is an effective and well-tolerated treatment for ABSSSI, including in patients who met SIRS criteria.
Ceftaroline Fosamil Associated With Shorter ABSSSI-Related Hospital Stay
Compared with vancomycin, patients with ABSSSI treated with ceftaroline fosamil had significantly shorter length of hospital stay.
Effect of Omadacycline on Cardiac Parameters in ABSSSI and CABP
Omadacycline was non-inferior to moxifloxacin for treatment of CABP and linezolid for treatment of ABSSSI.
Omadacycline Noninferior to Linezolid in ABSSSI Patients With High BMI, Diabetes
The goal of this post-hoc analysis of OASIS-1 study was to determine if BMI or T2D had any effect on the efficacy or safety of omadacycline relative to linezolid.
Intramuscular Benzathine Penicillin Reduced Incidence of Recurrent Cellulitis
Although intramuscular antibiotics had been suggested as a prevention strategy for recurrent cellulitis, the evidence is scarce.
Worse Outcomes With Acute Skin Plus Bloodstream Infections
Researchers evaluated risk factors associated with secondary bloodstream infections in patients with acute bacterial skin and skin structure infections.
Treating ABSSSI in Diabetes: Efficacy of Dalbavancin Examined
Dalbavancin has shown potent activity against gram-positive pathogens responsible for ABSSSI, including MRSA.
Fournier’s Gangrene: Incidence, Risk Factors, and Adverse Outcomes
Study suggests a higher incidence of Fournier’s gangrene than previously described.
Cost Effectiveness of Dalbavancin, Oritavancin in Acute Skin Infections
Dalbavancin and oritavancin may make it possible to allow for earlier discharge and reduce health care costs without compromising efficacy.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in In-Depth Focus from IDWeek 2017: Skin Infections
Loading... 
Loading...